Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.
Elife
; 92020 06 23.
Article
in English
| MEDLINE | ID: covidwho-611846
ABSTRACT
We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and soluble forms of the receptor for the virus, angiotensin converting enzyme 2. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Immunization, Passive
/
Coronavirus Infections
Type of study:
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Year:
2020
Document Type:
Article
Affiliation country:
ELife.57877
Similar
MEDLINE
...
LILACS
LIS